Analysts’ Recommendations for Bioverativ in January 2018

Recent developments

In October 2017, Bioverativ (BIVV) and Sangamo Therapeutics (SGMO) announced that the FDA had accepted their Investigational New Drug (or IND) application for STR-400, a gene-edited therapy for the treatment of individuals with transfusion-dependent beta-thalassemia.

The acceptance of IND allows Sangamo Therapeutics to start a Phase 1/2 clinical trial for the evaluation of the safety, efficacy, and tolerability of ST-400 in adult individuals with transfusion-dependent beta-thalassemia.

Analysts’ Recommendations for Bioverativ in January 2018

Sangamo Therapeutics and Bioverativ are jointly developing ST-400 as part of an exclusive worldwide collaboration for the development and commercialization of gene-edited cell therapies for beta-thalassemia and sickle cell disease.

Analysts’ recommendations

Fourteen analysts were tracking Bioverativ in January 2018. Four analysts recommended “strong buys,” while two recommended “buys” on the stock. Seven analysts recommended “holds” on Bioverativ stock, and one analyst recommended a “sell.”

On January 6, 2018, Bioverativ had a consensus 12-month target price of $62.45, which represents an 11.9% potential return on investment over the next 12 months. The iShares Core S&P Mid-Cap ETF (IJH) invests ~0.34% of its total portfolio holdings in Bioverativ.

Peers’ ratings

Of the 27 analysts tracking Vertex Pharmaceuticals (VRTX) in January 2018, ~85% recommended some form of a “buy” rating on the stock, while the rest recommended “holds.” On January 5, 2018, Vertex Pharmaceuticals had a consensus 12-month target price of $183.29, representing the potential for a 17.8% return on investment over the next 12 months.

Of the 13 analysts tracking Neurocrine Biosciences (NBIX) in January 2018, five recommended “strong buys” on the stock, while eight recommended “buys.” On January 5, 2018, Neurocrine Biosciences had a consensus 12-month target price of $90.92, representing the potential for an 11.2% return on investment over the next 12 months.

Of the ten analysts tracking Agios Pharmaceuticals (AGIO) in January 2018, 90% recommended some form of a “buy” rating on the stock, while one analyst recommended a “hold.” On January 5, 2018, Agios Pharmaceuticals had a consensus 12-month target price of $77.67, representing the potential for a 26.7% return on investment over the next 12 months.